UCB Inc. Nov. 4 announced that the Food and Drug Administration has accepted for filing its supplemental new drug application for Vimpat (lacosamide) as monotherapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older.
Vimpat already is approved as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older.
UCB is based in Brussels, Belgium.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.